A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Srdan Verstovsek, Ruben A. Mesa, Mohamed E. Salama, Li Li, Celine Pitou, Fabio P. Nunes, Gregory L. Price, Jennifer L. Giles, Deborah N. D'Souza, Richard A. Walgren, Josef T. Prchal

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia'. Together they form a unique fingerprint.

Medicine & Life Sciences